AbbVie Expands Oxford RD Facility
AbbVie has expanded its UK research and development facility in Oxford as part of a more than 120 million pound investment. The new site will broaden research capabilities across immunology, neuroscience, and oncology.
Insights:
AbbVie expanded its research and development facility in Oxford as part of a £120 million-plus ($161 million) investment, the drugmaker said on Wednesday morning. The expansion follows an agreement between the United States and the United Kingdom aimed at aligning UK medicine prices with new US policies. The investment strengthens regional research capabilities in immunology, neuroscience, and oncology.
